BenevolentAI co-founder Kenneth Mulvaney says he is taking the AI drug discovery specialist back to its “techbio” foundation in a restructuring announced by the firm Wednesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,